IP Watchdog

MARCH 21, 2025

This week in Barks & Bites: American pharmaceutical firm Johnson & Johnson announces $55 billion in U.S. This week in Barks & Bites: American pharmaceutical firm Johnson & Johnson announces $55 billion in U.S. by BOE Technology. by BOE Technology.

Pharmaceuticals 52

Pharmaceuticals Construction Litigation Technology 52

IP Watchdog

JULY 30, 2021

This week in Other Barks & Bites: a German high court rules that Lindt’s gold foil-wrapped chocolate bunnies have trademark protections; Federal Circuit Judge Kathleen O’Malley announces her retirement; the Federal Circuit rules that the PTAB gave no meaningful opportunity to respond to a sua sponte claim construction order; InterDigital obtains (..)

Court Rules 105

Court Rules Pharmaceuticals Construction 105

IP Watchdog

NOVEMBER 6, 2023

Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Actelion Pharmaceuticals Ltd. Mylan Pharmaceuticals Inc. Today, the U.S. vacating an infringement judgment against Mylan in the Northern District of West Virginia.

Evidence 105

Evidence Pharmaceuticals Construction Litigation 105

IP Watchdog

NOVEMBER 8, 2023

Court of Appeals for the Federal Circuit issued yet another decision reinforcing what can only be described as the “lead compound” rule for challenging pharmaceutical and other chemical compound patents on the basis of obviousness. The Federal Circuit has been utilizing the “lead compound” construct since around 2000. Otsuka Pharm.

Construction 52

Construction Pharmaceuticals Litigation 52

IP Watchdog

MAY 3, 2022

Venture appealed the district court decision challenging “(I) [the] rejection of its on-sale-bar defense, (II) [the] determination that it infringed two patents we have since held invalid, (III) [the] construction of two claim terms, and (IV) [the] decision to enhance damages.”

Counterclaim 116

Counterclaim Construction Healthcare Pharmaceuticals 116

IP Watchdog

JULY 13, 2023

The district court’s decision highlights a clear tension between claim construction and enablement that, if left to stand, could permit pharmaceutical companies to block lower-cost generic medications with patents they did not actually invent.

Technology 52

Technology Pharmaceuticals Construction Evidence 52

Complex Discovery

OCTOBER 15, 2024

These enforcement actions targeted critical sectors, including pharmaceuticals, healthcare, technology, and energy. The “Other” category, which includes industries such as construction and educational services, made up 22.1%. For instance, the FTC challenged Amgen’s $27.8 of the total​.

Pharmaceuticals 59

Pharmaceuticals Healthcare Technology Manufacturing 59